Ehab Atallah, MD
Enriched profileProfessor of Medicine; Associate Director, Cancer Service Line · Medical College of Wisconsin
Ehab Atallah is Professor of Medicine; Associate Director, Cancer Service Line at Medical College of Wisconsin. OpenAlex indexes 361 publications with 4,801 citations (h-index 35); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Ehab Atallah, MD, is Professor of Medicine at Medical College of Wisconsin, Division of Hematology and Oncology. The public record shows 361 publications with 4,801 citations (h-index 35), centered on Leukemia (AML/ALL/CML/CLL), MDS / MPN, Lymphoma. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 23 companies, 1 NIH-funded awards (2014–2019).
- Most recent indexed publication: 2025 · Hematology (Amsterdam, Netherlands)
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Blinatumomab Consolidation in Real World
Sponsor: Medical College of Wisconsin
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
Sponsor: Eastern Cooperative Oncology Group
Industry payments
Updated 16 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20259 payments$21,970openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.3%Kinase inhibitor36.6%Brukinsa26%Bosulif18%Calquence18%Sprycel15%Imatinib Mesylate12%Jakafi11%Part D<11 patientsBCL-2 Inhibitor11.4%Venclexta100%Part D≥15 patients+ 1 more class in this area
Dermatology
24.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.5%Acyclovir100%Part D≥37 patientsAnti-infectives
9.8%Fluoroquinolone Antibacterial5.6%Levofloxacin100%Part D≥15 patientsAzole Antifungal4.2%Posaconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2014–2019 per NIH RePORTER. The latest:
- Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
Medical College of Wisconsin
FY2019$361,156R01CA184798 - Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
Medical College of Wisconsin
FY2018$620,114R01CA184798 - Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
Medical College of Wisconsin
FY2017$257,562R01CA184798
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Hematology (Amsterdam, Netherlands)
Article2025 - Real-world Management of CML: Outcomes and Treatment Patterns.
Current hematologic malignancy reports
Review2023 - Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges.
JCO oncology practice
Article2022
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ehab-atallah-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
aamds.org/podcast/dr-ehab-atallah-explains-transplant-mds-older-patients
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - Other
cmleukemia.com/dr-ehab-atallah.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cmleukemia.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
- Internal Medicine residency
Cleveland Clinic Health System
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Hematology/Oncology fellowship
Karmanos Cancer Institute (Chief Fellow)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Leukemia fellowship
MD Anderson Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Board Certified
Internal Medicine
- Board Certified
Hematology
- Board Certified/Eligible
Medical Oncology
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog-ecog-acrin.org ↗
- Administrative Director
H. Jean Khoury Cure CML Consortium (HJKC3), 21-center academic CML research collaborative
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →froedtert.com ↗
Media & interviews
press, podcasts and appearances- "What About My CML" patient education video series
segments including "CML and the COVID-19 Pandemic" and "The Good Cancer"
2021provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cmleukemia.com ↗ - OncLive contributing author/video commentator
"Atallah Breaks Down Key Advances Made Across Leukemias and Lymphomas" and ongoing OncLive author profile
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - MCW Cancer Center public talk
"Leukemia, What You Need to Know"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Razelle Kurzrock, MD
Medical College of Wisconsin
Mary Horowitz, MD
Medical College of Wisconsin
Reza Shaker, MD
Medical College of Wisconsin
Michael Widlansky, MD
Medical College of Wisconsin
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center